Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Bogenrieder

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Breast Cancer Research : BCR|January 16, 2021
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancerPeter Schmid, Marie-Paule Sablin, Jonas Bergh, et al.
British Journal of Cancer|March 13, 2020
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumoursJohann de Bono, Chia-Chi Lin, Li-Tzong Chen, et al.
The Journal of Investigative Dermatology|March 22, 2003
Stroma formation and angiogenesis by overexpression of growth factors, cytokines, and proteolytic enzymes in human skin grafted to SCID miceClaus J Gruss, Kapaettu Satyamoorthy, Carola Berking, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Breast Cancer Research : BCR|January 16, 2021
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancerPeter Schmid, Marie-Paule Sablin, Jonas Bergh, et al.
British Journal of Cancer|March 13, 2020
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumoursJohann de Bono, Chia-Chi Lin, Li-Tzong Chen, et al.
The Journal of Investigative Dermatology|March 22, 2003
Stroma formation and angiogenesis by overexpression of growth factors, cytokines, and proteolytic enzymes in human skin grafted to SCID miceClaus J Gruss, Kapaettu Satyamoorthy, Carola Berking, et al.
Pageof 4